



# Rabbit Anti-Palivizumab polyclonal antibody (CABT-ZB271)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Product Overview</b>	CABT-ZB271 is produced from sera of a rabbit immunized with Palivizumab.
<b>Specificity</b>	The product is specific for Palivizumab.
<b>Target</b>	Palivizumab
<b>Immunogen</b>	Palivizumab
<b>Isotype</b>	IgG
<b>Source/Host</b>	Rabbit
<b>Purification</b>	Affinity purification
<b>Conjugate</b>	Unconjugated
<b>Applications</b>	Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. Recommended Working Concentration: 0.05-1 µg/ml
<b>Reconstitution</b>	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
<b>Format</b>	Purified, Lyophilized.
<b>Size</b>	40 µg
<b>Buffer</b>	Lyophilized with PBS, pH 7.4, contains 0.02% sodium azide.
<b>Preservative</b>	0.02% sodium azide

<b>Storage</b>	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
<b>Ship</b>	Wet ice

## BACKGROUND

<b>Introduction</b>	Palivizumab with trade name Synagis, is an FDA-approved drug for the prevention of respiratory syncytial virus (RSV) infections. It is a recombinant humanized IgG1 kappa isotype monoclonal antibody. Palivizumab binds the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process.
---------------------	---

<b>Keywords</b>	Rabbit polyclonal antibody to Synagis; HSDB 8178; MEDI 493; Palivizumab
-----------------	---

## GENE INFORMATION

<b>Synonyms</b>	Rabbit polyclonal antibody to Synagis; HSDB 8178; MEDI 493; Palivizumab
-----------------	---